|
n
|
Mean
|
Range
|
---|
Patients (n)
|
50
| | |
Age (years)
| |
67
|
41 to 77
|
PSA (ng/ml)
| |
37
|
2.7 to 168
|
Gleason score
| |
8
|
6 to 10
|
Estimated risk of locoregional lymph node metastases (%)a
| |
32
|
3.3 to 80.3
|
- aAccording to the Cagiannos pre-treatment nomogram, where age, pre-treatment PSA, clinical tumour stage, primary and secondary Gleason grade, and the number of positive and negative biopsy cores influence the estimated risk.